These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34109568)

  • 1. Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia.
    Reyes-Travé A; Guarga-Solé L; Roig-Izquierdo M; Alonso-Pérez E; Clopés-Estela A; Delgadillo-Duarte J
    Pharmacoeconomics; 2021 Sep; 39(9):973-982. PubMed ID: 34109568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain).
    Guarga L; Gasol M; Reyes A; Roig M; Alonso E; Clopés A; Delgadillo J
    Value Health; 2022 May; 25(5):803-809. PubMed ID: 35500950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 5. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
    Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
    BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 8. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-sharing agreements, present and future.
    Gonçalves FR; Santos S; Silva C; Sousa G
    Ecancermedicalscience; 2018; 12():823. PubMed ID: 29743943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining and Measuring the Affordability of New Medicines: A Systematic Review.
    Antoñanzas F; Terkola R; Overton PM; Shalet N; Postma M
    Pharmacoeconomics; 2017 Aug; 35(8):777-791. PubMed ID: 28477220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data.
    Holleman MS; Uyl-de Groot CA; Goodall S; van der Linden N
    Value Health; 2019 Mar; 22(3):322-331. PubMed ID: 30832970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe.
    Mills M; Kanavos P
    Health Policy; 2020 Mar; 124(3):239-251. PubMed ID: 31926651
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.